

*R1.126* 16. *15* 69. The method of claim 68 wherein the protein which is competent to transport potassium across a membrane is human.

*R1.126* 17. *15* 70. The method of claim 68 wherein the cell expressing the potassium transport protein is transformed with a self replicating vector comprising a nucleic acid sequence encoding a mammalian protein comprising 2 P domains and 4 transmembrane segments, which protein is competent to transport potassium across a membrane.

*R1.126* 18. *17* 71. The method of claim 70 wherein the self replicating vector comprises a nucleic acid sequence encoding a human potassium transport protein.

*R1.126* 19. *18* 72. The method of claim 71 wherein the self replicating vector comprises SEQ ID. No. 1.

*R1.126* 20. *15* 73. A substance, identified by the method of claim 68, which is capable of positively or negatively influencing the transport activity of a potassium transport channel.

*R1.126* 21. *20* 74. The substance of claim 73 which influences the transport activity of the potassium transport channel comprising 2 P domains and 4 transmembrane segments.

*R1.126* 22. *21* 75. The substance of claim 74 which influences the transport activity of the potassium transport channel represented by SEQ ID. No. 2.

*R1.126* 23. *20* 76. A pharmaceutical composition for the treatment of diseases caused by the malfunction of a potassium transport channel, comprising the substance of claim 73.